Market closedADR

Bicycle Therapeutics/$BCYC

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Ticker

$BCYC

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United Kingdom

Employees

284

Website

www.bicycletherapeutics.com

BCYC Metrics

BasicAdvanced

$1B

-

-$3.23

0.89 -

Price and volume

Market cap

$1B

Beta

0.89

52-week high

$27.24

52-week low

$12.17

Average daily volume

702K

Financial strength

Current ratio

17.13

Quick ratio

16.822

Long term debt to equity

0.666

Total debt to equity

1.334

Interest coverage (TTM)

-78.64%

Management effectiveness

Return on assets (TTM)

-15.01%

Return on equity (TTM)

-26.67%

Valuation

Price to revenue (TTM)

21.179

Price to book

1.26

Price to tangible book (TTM)

1.26

Price to free cash flow (TTM)

-3.84

Growth

Revenue change (TTM)

48.60%

Earnings per share change (TTM)

-35.25%

3-year revenue growth (CAGR)

46.34%

3-year earnings per share growth (CAGR)

3.98%

What the Analysts think about BCYC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.

BCYC Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

BCYC Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BCYC News

AllArticlesVideos

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 weeks ago

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Business Wire·1 month ago

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCYC

$

Capital at risk

Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Bicycle Therapeutics stock?

Bicycle Therapeutics (BCYC) has a market cap of $1B as of January 15, 2025.

What is the P/E ratio for Bicycle Therapeutics stock?

The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of January 15, 2025.

Does Bicycle Therapeutics stock pay dividends?

No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Bicycle Therapeutics dividend payment date?

Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.

What is the beta indicator for Bicycle Therapeutics?

Bicycle Therapeutics (BCYC) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.